Salugen AG (SYMBOL: SQZ.F) Successfully Conducts Frankfurt Stock Exchange Listing

Share Article

Salugen shares rise over 70 percent in the first month as the first publicly-traded nutrigenomics company is listed on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange)

Salugen® AG (http://www.salugen.com), a life sciences company, announces the successful listing of its stock traded on the FWB® Frankfurter Wertpapierbörse (the Frankfurt Stock Exchange) under the symbol SQZ (FRA:SQZ.F). In its first month Salugen's share price increased over 70 percent despite uncertain economic times affecting the overall equity markets and is currently near its listing price.

The Company is raising capital to invest in growing its commercial infrastructure in Europe and the USA, as well as exploring further growth through additional acquisitions. The banking institutions involved in the transaction include investment bank Sherbrooke Equity AG.

Salugen began in early 2005 as a pioneer in nutritional genetics. In a few short years, the Company emerged from its "pilot stage" positioned to capture significant market share. Besides winning numerous awards for its research by the Natural Products Association, the largest natural products association in North America, some of the accomplishments of the first three years include:

  • Conducting a dozen commercial pilots in Europe and the USA to evaluate the viability of nutrigenomics for joint health, obesity, alcoholism, illegal drug abuse, narcotic abuse, skin health, stress and other conditions;
  • Gaining rights to multiple issued and pending intellectual property protections in Europe and the USA, as well as registering important trademarks;
  • Completing multiple clinical studies and having over 15 publications in peer-reviewed scientific and medical journals;
  • Going from start-up to about $1M in sales in its first year of commercial piloting demonstrating explosive growth potential; and,
  • Accomplishing these features on less than 1/10th of the funding of other companies in nutritional genetics.

To prepare Salugen for this milestone, the Company has participated in various programs to support its growth including being a member of the Morrison & Foerster Venture Network (http://www.mofo.com), a graduate of the San Diego CONNECT Springboard Program (http://www.connect.org), and a presenter at the Nutritional Capital Network (http://www.nutritioncapital.com).

This release follows a German news release on April 13, 2009 http://www.irw-press.com/news_6944.html.

About Salugen AG
Salugen™ is a life sciences company offering nutritional ingredients and gene testing to help reduce excessive cravings involved in smoking, weight problems, and alcohol and drug abuse. Salugen has a patent-protected, clinically proven nutritional formulation to reduce stress and cravings, as well as patent-protected gene tests to help identify these persons and customize their treatment. Simply, Salugen's goal is to reduce or eliminate the illness, costs, and deaths associated with these preventable disorders. For additional information about the company, please visit http://www.salugen.com.

Investor Relations Information Contact:
Petjo Noack, MA and Louis Philippe Antunes
Sherbrooke Equity Inc.
Seefeldstrasse 45
8032 Zürich
Tel.: 41 (0) 43 443 70 70
Fax.: 41 (0) 43 443 70 77

Web: http://www.sherbrookequity.com

Company Information Contact: Salugen AG, 877-258-4360

Forward Looking Statements
Certain statements in this press release are forward-looking. These forward-looking statements include references to the use of our laboratory tests and nutritional products. These forward-looking statements are subject to risks and uncertainties and other factors, which may cause actual results to differ materially from the anticipated results or other expectations expressed in such forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that physicians may not use the testing or products correctly; risks and uncertainties relating to the performance of our products; the growth in revenues; the size, timing and success or failure of any clinical trials; whether larger confirmatory clinical studies will confirm the results of initial studies; our ability to establish reliable, high-volume operations at commercially reasonable costs; expected reliance on physicians selling our products for a majority of our revenues; the annual renewal of certain customer agreements; actual market acceptance of our products and adoption of our technological approach and products; our estimate of the size of our markets; our estimates of the levels of demand for our products; the impact of competition; whether payers will authorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services; whether actions by the FDA, FTC or any other state regulatory body will restrict our ability to commercialize our products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; and whether we will be able to raise sufficient capital in the future, if required. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Brian Meshkin
Visit website